-
Stocks move lower despite oil prices dropping
-
Brazil's patron saint pulled into latest election scrap
-
AI driving up innovation investment: UN
-
Football overload leaves players near 'breaking point', warns Tebas
-
UN Security Council extends Haiti mission by 6 months
-
Paris Eiffel Tower says chief to step down after uproar over removing women staff
-
Man Utd do not deserve medals if Man City stripped of titles: Rooney
-
Amaze Holdings (NYSE: AMZE) Executes Binding LOI to Acquire BullionFX | Alchemy, a Decentralized Gold-Backed Financial Ecosystem for Valued at US$155 Million
-
Vana Completes Expanded Staking as Part of the Vega Upgrade, Publishes Expanded VANA Token Economics
-
Clashes between French teens, police as school blockades intensify
-
Spain to cap gas price hikes, extend fuel discounts
-
Stocks move sideways despite oil moving lower
-
'We just need rain': Germany's Rhine river hits new low
-
African leaders to gather in Egypt for business summit
-
Yemen health system at 'breaking point': WHO
-
UK decides against charging foreign visitors for museums
-
Ireland undecided on second Israel match: coach
-
Dallaglio to sell England World Cup winners' medal
-
France's Le Pen defiant after top ally hit by antisemitism claims
-
Brazil come from behind to beat Australia 4-2 in friendly
-
Tom Cruise trades stunts for satire as toxic tycoon 'Digger'
-
Ruthless An retains Asian Games badminton crown as Kunlavut triumphs
-
MEXC Unveils "WE SEE YOU" Brand Visual Refresh, Putting People Behind Every Trade in Focus
-
Alonso to stay with F1 team Aston Martin in 2027
-
Thai capital cleans up after deadly floods
-
China badminton 'still strong' despite Asian Games slump
-
NATO, EU allies rally to Estonia after 'sabotage' blamed on Russia
-
'Exceptional' Turner painting shown in Rome before sale
-
Families demand justice for Cameroon's 'nightmare' wave of murdered women
-
European stocks climb as oil dips
-
Tebas says Man City should face 'most severe' sanctions if guilty of rule breaches
-
Spain aims to ban evictions until 2030 amid housing protests
-
Pochettino calls Man City success 'a period of deception'
-
Kunlavut first Thai man to win Asian Games badminton singles gold
-
Settler attack on West Bank village injures Israeli forces, drawing rare rebuke
-
French far right says antisemitism claims part of 'total war' to derail presidency bid
-
Mystery over UK airbase scare after reports no explosives found
-
'Gift from God': Rain brings relief from Indonesia toxic haze
-
Spanish govt races to adopt housing law under protest pressure
-
Ex-world snooker champion jailed for 7 years for child sex crimes
-
Estonia slams Russian 'sabotage' after arson attack on defence company
-
French teens clash with police as school blockades intensify
-
Slovenia sees surge in '.si' sites after Trump hypes 'super intelligence'
-
FIFA accuses UEFA of 'misinformation campaign' in bid for World Cup papers
-
'Like a dream' for An as Games organisers 'sorry' for latest mix-up
-
Myanmar airstrike toll hits 50 as families gather dead
-
Tokyo suffers longest streak of rainy days on record
-
STARTRADER Raises Lloyd's of London Client Fund Insurance to USD 30 Million in Aggregate
-
Indonesia charges train driver over crash that killed 16 women
-
North Korean DMZ landmine blasts 'violation of armistice': Seoul
US House votes for life-changing $35 insulin price cap
US lawmakers voted Thursday on a bill limiting the cost of insulin to $35 a month, a transformative curb for millions of diabetics who pay hundreds of dollars for the life-sustaining hormone.
Drug pricing has vexed politicians for years in the United States, which has the highest annual health expenditure of any industrialized country, at around $11,000 per capita.
Insulin costs the 7.4 million American adults who use it to manage their diabetes eight times as much as in other wealthy nations, according to a 2020 study commissioned by the Health and Human Services Department.
"This is a kitchen table issue: are people going to be able to pay their bills? And it is, for us, a step in the direction of the (government) being able to negotiate for lower drug prices beyond insulin," House Speaker Nancy Pelosi told reporters.
The legislation passed the House of Representatives by 232 votes to 193, with a handful of Republicans crossing the aisle to join the Democrats, and now advances to the upper chamber of Congress, the US Senate.
It would require private health insurance companies to set prices for a month's supply of insulin at no more than $35, or 25 percent of a plan's negotiated price, whichever is lower, starting in 2023 for some patients and 2024 for all.
The cap was a provision in President Joe Biden's "Build Back Better" social welfare bill that was torpedoed by Democratic infighting in Congress late last year.
Biden brought the issue back into the spotlight during his State of the Union address on March 1, reinvigorating calls for action on pricing from diabetes advocates.
The effort is being seen as the only way for Democrats to show they're capable of acting on sky-high prescription drug prices before November's midterm elections.
- 'Costing a lot' -
The Senate is holding its own cross-party negotiations on driving down insulin costs by targeting the middlemen between health insurance companies and pharmacies.
And a separate Democrat-only bill from Georgia's Senator Raphael Warnock that would also cap the price at $35 is likely to be combined with the effort.
"I'm a pastor -- I'm on the ground -- and so I know that everybody knows somebody with diabetes," Warnock said in a video promoting his initiative.
Senate Majority Leader Chuck Schumer told reporters last week he believed a bipartisan bill had a good chance of passing when lawmakers return from a break at the end of April.
Research suggests that more than a quarter of Americans with type 1 diabetes have had to ration insulin they could not afford. Campaigners say the proportion went up to 50 percent during the pandemic.
It remains unclear if any legislation can gain the 10 Republican votes needed to advance in the Senate, but some opposition lawmakers have shown interest in an issue that affects voters across the board.
"I'd be for some kind of regulation where we can help. Too many people (are) paying thousands of dollars a month. I'm not big on regulating process, but that one's costing a lot of people a lot of money," Alabama Senator Tommy Tuberville told Axios.
Republicans on the powerful House Ways and Means Committee described the vote as "the largest expansion of federal command and control in Americans' private health insurance design" since the Affordable Care Act, the landmark 2010 regulatory overhaul and expansion of health care coverage.
"Democrats are reviving their socialist drug pricing scheme from their failed radical tax and spending spree," the committee's top Republican Kevin Brady said in a statement.
A.Moore--AT